Literature DB >> 32789796

Ibuprofen Exerts Antiepileptic and Neuroprotective Effects in the Rat Model of Pentylenetetrazol-Induced Epilepsy via the COX-2/NLRP3/IL-18 Pathway.

Rui Liu1, Shuhua Wu2, Chong Guo1, Zhongbo Hu1, Jiangtao Peng1, Ke Guo1, Xinfan Zhang1, Jianmin Li3.   

Abstract

Epilepsy is one of the most common diseases of the central nervous system. Recent studies have shown that a variety of inflammatory mediators play a key role in the pathogenesis of the disease. Ibuprofen (IBP) is a well-known anti-inflammatory agent that reduces the neuroinflammatory response and neuronal damage. In this study, we examined the effect of IBP in a rat model of pentylenetetrazol (PTZ)-induced chronic epilepsy. PTZ injection was given a total of 15 times on alternate days (over a period of 29 days) to induce epilepsy. The effects of IBP were evaluated by behavioral observation, EEG recording, Nissl staining, immunohistochemistry, Western blot analysis, and electrophysiological recording. The results showed that IBP alone affected the expression of cyclooxygenase-2 (COX-2) and neuronal excitability but did not cause epilepsy. IBP reduced seizure scores in the PTZ-treated rats, and it minimized the loss of hippocampal neurons. In addition, IBP decreased the secretion of COX-2, inhibited the activation of the NOD-like receptor 3 inflammasome, and reduced the secretion of the inflammatory cytokine interleukin-18. Furthermore, the results of whole-cell patch-clamp revealed that IBP affected action potential properties, including frequency, latency and duration in epileptic rats, suggesting that it may impact neuronal excitability. These effects of IBP may underlie its antiepileptic and neuroprotective actions.

Entities:  

Keywords:  Action potential; Cyclooxygenase-2; Epilepsy; Ibuprofen; NOD-like receptor 3; Neuroprotection

Mesh:

Substances:

Year:  2020        PMID: 32789796     DOI: 10.1007/s11064-020-03109-9

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  7 in total

Review 1.  Therapeutic implications of cyclooxygenase (COX) inhibitors in ischemic injury.

Authors:  Heena Khan; Kunal Sharma; Amit Kumar; Amarjot Kaur; Thakur Gurjeet Singh
Journal:  Inflamm Res       Date:  2022-02-17       Impact factor: 4.575

2.  Vitamin E Exerts Neuroprotective Effects in Pentylenetetrazole Kindling Epilepsy via Suppression of Ferroptosis.

Authors:  Xinfan Zhang; Shuhua Wu; Chong Guo; Ke Guo; Zhongbo Hu; Jiangtao Peng; Zhao Zhang; Jianmin Li
Journal:  Neurochem Res       Date:  2021-11-15       Impact factor: 3.996

3.  LncRNA ZNF883-Mediated NLRP3 Inflammasome Activation and Epilepsy Development Involve USP47 Upregulation.

Authors:  Lina Gong; Yaru Han; Ru Chen; Pu Yang; Chen Zhang
Journal:  Mol Neurobiol       Date:  2022-06-09       Impact factor: 5.682

4.  Effect of Parecoxib Sodium Preemptive Analgesia on the Recovery Period of General Anesthesia in Patients Undergoing Glioma Resection.

Authors:  Lijuan Zhu; Hui Guo; Tao Zheng; Jing Zhu
Journal:  J Oncol       Date:  2022-06-13       Impact factor: 4.501

Review 5.  Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside.

Authors:  Awanish Mishra; Ritam Bandopadhyay; Prabhakar Kumar Singh; Pragya Shakti Mishra; Neha Sharma; Navneet Khurana
Journal:  Metab Brain Dis       Date:  2021-08-13       Impact factor: 3.584

6.  Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole‑kindled mice.

Authors:  Lei Wang; Jiangwei Ding; Changliang Zhu; Baorui Guo; Wu Yang; Wenxin He; Xinxiao Li; Yangyang Wang; Wenchao Li; Feng Wang; Tao Sun
Journal:  Int J Mol Med       Date:  2021-10-22       Impact factor: 4.101

7.  Trichopus zeylanicus ameliorates ibuprofen inebriated hepatotoxicity and enteropathy: an insight into its modulatory impact on pro/anti-inflammatory cytokines and apoptotic signaling pathways.

Authors:  Nagesh Kishan Panchal; Purushotham Swarnalatha; Sabina Evan Prince
Journal:  Inflammopharmacology       Date:  2022-08-25       Impact factor: 5.093

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.